What You Need To Know
Please review the New Jersey Department of Health recommendation to continue the administration of Respiratory Syncytial Virus (RSV) monoclonal antibody products through April 30, 2026.
Key Points:
- Health care providers caring for children should consider administering RSV monoclonal antibodies, nirsevimab or clesrovimab, through April 30, 2026.
- Current surveillance data nationally and in New Jersey indicate a later and prolonged RSV season compared with historical patterns.
- RSV remains the leading cause of infant hospitalizations in the United States, underscoring the importance of optimizing prevention strategies throughout a prolonged season.
- The New Jersey Vaccines for Children (VFC) Program continues to have an ample supply of both nirsevimab and clesrovimab, which is available for ordering through NJIIS. VFC-enrolled providers are encouraged to order the products to serve their eligible populations.